المؤلفون: Barbara A. Myers, Rachel Klingensmith, Mary de Groot

المصدر: Diabetes Care. 45:42-58

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, Type 2 diabetes, Anxiety, Young Adult, Diabetes mellitus, Internal Medicine, medicine, Humans, Prediabetes, Psychiatry, Pandemics, Depression (differential diagnoses), Advanced and Specialized Nursing, Type 1 diabetes, Depression, SARS-CoV-2, business.industry, COVID-19, Middle Aged, medicine.disease, Patient Health Questionnaire, Distress, Diabetes Mellitus, Type 2, Female, medicine.symptom, business, Stress, Psychological

الوصف: OBJECTIVE To compare the mental health experiences associated with coronavirus disease 2019 (COVID-19) in adults with and without diabetes. RESEARCH DESIGN AND METHODS Between 29 May 2020 and 30 June 2020, 2,176 U.S. adults completed an online survey including demographics, COVID-19 experiences, depression (eight-item Patient Health Questionnaire) and anxiety (seven-item Generalized Anxiety Disorder) symptoms, perceived stress (10-item Perceived Stress Scale), resilience (Brief Resilience Scale), and diabetes-related distress (in participants with diabetes) (17-item Diabetes Distress Scale). RESULTS Mean age was 49.6 years (SD 16.9); participants were primarily women (80.0%) and White (88.3%), with an annual household income of ≥$60,000 (57.6%). One hundred reported a diagnosis of type 1 diabetes (4.6%), 304 type 2 diabetes (13.9%), and 145 prediabetes (6.6%). Nearly one-third (29.7%) indicated decreases in income attributable to the pandemic. Participants with type 1 diabetes had higher levels of diabetes distress than participants with type 2 diabetes (P < 0.05), with moderate severity in both groups. Participants with type 2 diabetes had significantly more comorbidities and COVID-19 risk factors than all other groups (all P < 0.01). After controlling for covariates, participants with type 2 diabetes reported significantly more depressive symptoms than those without diabetes (P < 0.05) and lower levels of resilience (P < 0.05). Subgroup analyses by sex and age indicated that women and younger adults, particularly those age 18–34 years, reported significantly more depression and anxiety symptoms, stress, and diabetes-related distress and lower levels of resilience than men and adults age ≥51 years. CONCLUSIONS In this naturalistic observational study, participants with type 2 diabetes reported more depression, lower resilience, and significantly more COVID-19 risk factors and medical comorbidities than participants without diabetes. Overall, our participants demonstrated worse depression and anxiety symptoms during compared with before the pandemic.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6219fe206f226624cbfa3fad262041Test
https://doi.org/10.2337/dc21-0769Test

المؤلفون: Katherine R. Tuttle, Radica Z. Alicic

المصدر: Diabetes

مصطلحات موضوعية: Adult, Blood Glucose, Male, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Type 2 diabetes, Disease, Kidney, Kidney Function Tests, Young Adult, chemistry.chemical_compound, Commentaries, Diabetes mellitus, Internal Medicine, Humans, Medicine, Diabetic Nephropathies, Hepatitis A Virus Cellular Receptor 1, Intensive care medicine, Dialysis, Retrospective Studies, Type 1 diabetes, business.industry, Mortality rate, medicine.disease, Transplantation, Diabetes Mellitus, Type 1, chemistry, Female, Glycated hemoglobin, business, Glomerular Filtration Rate

الوصف: Diabetes, the “other pandemic,” has progressively increased in magnitude despite advances in knowledge about diabetes prevention over the last two decades (1). Therefore, diabetes will remain a major public health problem for the foreseeable future. More patients with diabetic complications inevitably accompany more people living with diabetes. Diabetic kidney disease (DKD) is one of the most serious, risky, and common, occurring in ∼30% of patients with type 1 diabetes and ∼40% of those with type 2 diabetes (2). Progressive DKD is now the foremost cause of kidney failure worldwide, accounting for half of all cases (3). However, in many regions, treatment for kidney failure by dialysis or transplantation is inaccessible and DKD becomes an unescapable death sentence. Indeed, DKD is now the most common cause of death in Mexico City (4). However, even such sobering observations fail to capture the true magnitude of the impact, as DKD independently increases risks of all-cause and cardiovascular mortality by more than fivefold even before patients develop kidney failure (5). Indeed, the mortality rate outpaces the rate of progression to kidney failure by more than 2:1 once macroalbuminuria develops (6). The need to find better ways to identify and treat DKD has never been more urgent. Recent therapeutic advances with the sodium–glucose cotransporter 2 inhibitors demonstrate clear benefits on top of the standard of care, yet substantial residual risk of kidney failure and death remains (7,8). Uncovering the biological basis of disease is essential to further therapeutic advancement. While hyperglycemia is a well-recognized DKD risk factor, the traditional biomarker of glycated hemoglobin is an average …

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14a39e6bacabe67cc294420e19eaf781Test
https://doi.org/10.2337/dbi21-0021Test

المؤلفون: German Tapia, Grethe S. Tell, Geir Joner, Torild Skrivarhaug, Lars C. Stene, Maryam Saeed, Inger Ariansen, Ingebjørg Seljeflot

المصدر: Diabetes Care

مصطلحات موضوعية: Adult, Research design, Cardiovascular and Metabolic Risk, medicine.medical_specialty, Galectin 3, Endocrinology, Diabetes and Metabolism, Population, Coronary Disease, 030209 endocrinology & metabolism, Cohort Studies, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Child, education, Advanced and Specialized Nursing, Type 1 diabetes, education.field_of_study, Tissue Inhibitor of Metalloproteinase-1, business.industry, medicine.disease, Coronary heart disease, Diabetes Mellitus, Type 1, Galectin-3, Cohort, business, Cohort study

الوصف: OBJECTIVE To study whether serum galectin-3 and other biomarkers of inflammation predict coronary heart disease (CHD) in subjects with long-standing childhood-onset type 1 diabetes. RESEARCH DESIGN AND METHODS A population-based nationwide cohort of 299 subjects with type 1 diabetes diagnosed in Norway at RESULTS Of 295 subjects, 40 (13.6%) had a documented CHD event during a mean follow-up of 14.4 years (range 0.5–16). IL-6 (aHR 1.32 [95% CI 1.07–1.63]), galectin-3 (aHR 1.44 [95% CI 1.09–1.80]), and TIMP-1 (aHR 1.37 [95% CI 1.04–1.81]) were significant predictors of CHD after adjustment for conventional risk factors. CONCLUSIONS Galectin-3 was significantly associated with future CHD in subjects with type 1 diabetes, and if the results are replicated in larger studies, it may aid in prediction together with conventional risk factors for CHD.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37fcd446da0c44f20b140d30fab2a213Test
https://doi.org/10.2337/dc20-1712Test

المؤلفون: Beatrice A. Pieri, Gabriella A.I. Bergin-Cartwright, Anna Simpson, Julian Collins, Anna Reid, Janaka Karalliedde, Anna Brackenridge, Matthew Hotopf, Sufyan Hussain

مصطلحات موضوعية: Advanced and Specialized Nursing, Adult, Cross-Sectional Studies, Diabetes Mellitus, Type 1, Depression, Endocrinology, Diabetes and Metabolism, Internal Medicine, Humans, Anxiety, Awareness, Hypoglycemia

الوصف: OBJECTIVE We tested the hypothesis that impaired awareness of hypoglycemia (IAH) is independently associated with symptoms of anxiety and depression in type 1 diabetes. RESEARCH DESIGN AND METHODS In this cross-sectional observational study in 950 adults with type 1 diabetes, associations were examined using multiple regression models, adjusting for sociodemographic and clinical characteristics. RESULTS Prevalence for probable anxiety, depression, and IAH were 9.4%, 9.8%, and 22.6%, respectively. When included in separate regression models, both depression and anxiety were independently associated with an increased odds of IAH and robust to adjustment (odds ratio 3.64 [95% CI 2.19–6.04] and 2.46 [1.46–4.14], respectively). Further analysis demonstrated a dose-response relationship between increased severity of probable mental disorder and increased odds of having IAH (P < 0.001). CONCLUSIONS The robust independent relationship between probable anxiety and depression with IAH demonstrates the need for routine psychological assessment and management of people with type 1 diabetes and IAH.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06eb05b0830a2abb90c3e81a8355783aTest
https://doi.org/10.2337/figshare.20405418Test

المؤلفون: Gemma Llauradó, Núria Amigó, Rocío Fuertes-Martín, Ana Romero, Albert Cano, Lara Albert, Olga Giménez-Palop, Eugenio Berlanga, Sonia Fernández-Veledo, Xavier Correig, Joan Vendrell, José-Miguel González-Clemente

مصطلحات موضوعية: Adult, Inflammation, Advanced and Specialized Nursing, Aging, Diabetes Mellitus, Type 1, Vascular Stiffness, Cardiovascular Diseases, Polysaccharides, Endocrinology, Diabetes and Metabolism, Internal Medicine, Humans, Pulse Wave Analysis, Biomarkers

الوصف: OBJECTIVE Vascular aging (arterial stiffness [AS]) is an inflammation-linked process that predicts macro- and microvascular complications in adults with type 1 diabetes (T1D). We evaluated the utility of measuring the inflammation-linked N-glycans GlycA and GlycB to assess vascular aging in adults with T1D. RESEARCH DESIGN AND METHODS Eighty-four adults with T1D (>10-year duration without cardiovascular events) and 68 healthy control subjects were evaluated for clinical characteristics (including microvascular complications in patients with T1D), aortic pulse wave velocity (aPWV) (surrogate measure of AS), and serum GlycA and GlycB (peak area [concentration] and height/width [H/W] ratio) using 1H-nuclear magnetic resonance spectroscopy. RESULTS Patients with T1D had higher median (interquartile range) values than healthy control subjects for (P < 0.001 for all comparisons) aPWV 7.9 (6.9–9.1) vs. 6.1 (5.5–6.7) m/s, GlycA 850.4 (781.3–916.1) vs. 652.4 (581.5–727.1) μmoL; GlycB 386.1 (353.2–426.3) vs. 310.0 (280.5–331.9) μmol/L), H/W ratio of GlycA 16.5 (14.9–18.1) vs. 15.0 (13.7–16.7), and H/W ratio of GlycB 5.0 (4.6–5.5) vs. 4.0 (3.4–4.3). Moreover, aPWV correlated (P < 0.001 for all correlations) with GlycA (r = 0.550) and GlycB (r = 0.423) concentrations and with H/W ratios of GlycA (r = 0.453) and GlycB (r = 0.510). Adjusting for potential confounders, GlycA concentration (β = 0.212, P < 0.001) and the H/W ratios of GlycA (β = 0.150, P = 0.009) and GlycB (β = 0.155, P = 0.011) remained independently associated with aPWV. C-statistics for detecting individuals with aPWV >10 m/s were 0.866 (95% CI 0.794–0.937) for GlycA levels and 0.862 (0.780–0.943) for H/W ratio of GlycB. CONCLUSIONS Measurement of serum GlycA and GlycB may have utility in assessing vascular aging in adults with T1D of >10-year duration and no previous cardiovascular events.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05d030083817df358453e566e2bbf808Test
https://doi.org/10.2337/figshare.20386962Test

المؤلفون: Courtney A. Balliro, Edward R. Damiano, Jordan Sherwood, Mallory A. Hillard, El-Khatib Firas H, Luz E. Castellanos, Evelyn Greaux, Steven Russell, Rabab Z. Jafri, Hui Zheng, Rajendranath Selagamsetty

المصدر: Diabetes Care

مصطلحات موضوعية: Adult, Bionics, Blood Glucose, Pancreas, Artificial, Pediatrics, medicine.medical_specialty, endocrine system diseases, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Bionic Pancreas, Hypoglycemia, Glucagon, Insulin Infusion Systems, MicroDose, Diabetes mellitus, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Insulin, Insulin lispro, Pancreas, Advanced and Specialized Nursing, Type 1 diabetes, business.industry, e-Letters: Observations, nutritional and metabolic diseases, medicine.disease, Diabetes Mellitus, Type 1, business, medicine.drug

الوصف: Reductions in blood glucose levels in people with diabetes are often achieved at the expense of increased hypoglycemia. A novel approach is to automatically deliver microdose glucagon when automation of insulin delivery alone is not sufficient to prevent hypoglycemia. The approach requires a bihormonal device and a stable form of glucagon or glucagon analog. The iLet bionic pancreas (Beta Bionics, Inc.) is a purpose-built, fully integrated device that receives a signal from a continuous glucose monitor (CGM) and contains autonomous, lifelong learning, mathematical dosing algorithms, which are initialized only with the patient’s body weight (1). We evaluated the function and safety of the iLet in both its insulin-only configuration and its bihormonal configuration delivering dasiglucagon, a chemically stable glucagon analog (Zealand Pharma), in a home-use study in adults with type 1 diabetes (T1D). This open-label, random-order, crossover, home-use trial (clinical trial reg. no. NCT03840278, ClinicalTrials.gov) was the first human study to test the bihormonal iLet configuration and the first multiday use of dasiglucagon in people with T1D (2). Ten participants used the insulin-only iLet for 7 days with insulin lispro (Eli Lilly) or aspart (Novo Nordisk), the bihormonal iLet for 7 days with dasiglucagon (4 mg/mL) and insulin lispro or aspart, or both, using the same glucose target (110 mg/dL), in random order. There were no restrictions on diet or exercise. The primary outcomes were prespecified iLet operational thresholds. The key secondary outcome was the median time with CGM glucose

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea6e8f7391460db6b0713ba3ff6fccaeTest
https://doi.org/10.2337/dc20-1086Test

المؤلفون: Wenjun Jiang, Jake A. Kushner, Michael J Davies, Helena W. Rodbard, Pablo Lapuerta, Ketan Dhatariya, Anne L. Peters, Phillip Banks, Darren K. McGuire, Sangeeta Sawhney, Thomas Danne

المصدر: Diabetes Care

مصطلحات موضوعية: Adult, Male, Research design, medicine.medical_specialty, Diabetic ketoacidosis, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, 030209 endocrinology & metabolism, Placebo, Diabetic Ketoacidosis, 03 medical and health sciences, Sodium-Glucose Transporter 1, 0302 clinical medicine, Double-Blind Method, Insulin, Regular, Human, Internal medicine, Diabetes mellitus, Internal Medicine, medicine, Humans, Glycosides, 030212 general & internal medicine, Adverse effect, Sodium-Glucose Transporter 2 Inhibitors, Advanced and Specialized Nursing, Type 1 diabetes, 3-Hydroxybutyric Acid, Emerging Therapies: Drugs and Regimens, business.industry, Incidence, Insulin, Incidence (epidemiology), medicine.disease, Diabetes Mellitus, Type 1, Treatment Outcome, Drug Therapy, Combination, Female, business, Follow-Up Studies

الوصف: OBJECTIVE To evaluate the incidence and risk factors for diabetic ketoacidosis (DKA) and related adverse events (AEs) in adults with type 1 diabetes treated with sotagliflozin adjunctive to insulin. RESEARCH DESIGN AND METHODS Data from two identically designed, 52-week, randomized studies were pooled and analyzed for DKA, changes in β-hydroxybutyrate (BHB), and percentage of patients with BHB >0.6 and >1.5 mmol/L. The patients were administered placebo, sotagliflozin 200 mg, or sotagliflozin 400 mg once daily. RESULTS A total of 191 ketosis-related AEs were reported, and 98 underwent adjudication. Of these, 37 events (36 patients) were adjudicated as DKA, with an exposure-adjusted incidence rate of 0.2, 3.1, and 4.2 events per 100 patient-years for placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg, respectively. No patient died of a DKA event. From a baseline BHB of ∼0.13 mmol/L, sotagliflozin treatment led to a small median increase over 52 weeks (≤0.05 mmol/L at all time points). Of sotagliflozin-treated patients, approximately 47% and 7% had ≥1 BHB measurement >0.6 mmol/L and >1.5 mmol/L, respectively (vs. 20% and 2%, respectively, of placebo-treated patients). Subsequent to the implementation of a risk mitigation plan, annualized DKA incidence was lower versus preimplementation in both the sotagliflozin 200 and 400 mg groups. CONCLUSIONS In patients with type 1 diabetes, confirmed DKA incidence increased when sotagliflozin was added to insulin compared with insulin alone. A lower incidence of DKA was observed following the implementation of an enhanced risk mitigation plan, suggesting that this risk can be managed with patient education.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1307dedc63a32d96131b84cbcb4384f7Test
https://doi.org/10.2337/dc20-0924Test

المؤلفون: Virginia Gabo, Ravi Reddy, Peter G. Jacobs, Deborah Branigan, Brian Senf, Navid Resalat, Florian H. Guillot, Katrina Ramsey, Nichole S. Tyler, Jessica R. Castle, Joseph El Youssef, Joseph Leitschuh, Isabelle Isa Kristin Steineck, Leah M. Wilson

المصدر: Diabetes Care. 43:2721-2729

مصطلحات موضوعية: Adult, Blood Glucose, Male, Pancreas, Artificial, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Urology, 030209 endocrinology & metabolism, Hypoglycemia, Artificial pancreas, Glucagon, Oregon, Young Adult, 03 medical and health sciences, Insulin Infusion Systems, 0302 clinical medicine, Diabetes mellitus, Outpatients, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Insulin, 030212 general & internal medicine, Exercise physiology, Exercise, Advanced and Specialized Nursing, Type 1 diabetes, Cross-Over Studies, business.industry, Middle Aged, medicine.disease, Crossover study, Diabetes Mellitus, Type 1, Hyperglycemia, Feasibility Studies, Female, business

الوصف: OBJECTIVE To assess the efficacy and feasibility of a dual-hormone (DH) closed-loop system with insulin and a novel liquid stable glucagon formulation compared with an insulin-only closed-loop system and a predictive low glucose suspend (PLGS) system. RESEARCH DESIGN AND METHODS In a 76-h, randomized, crossover, outpatient study, 23 participants with type 1 diabetes used three modes of the Oregon Artificial Pancreas system: 1) dual-hormone (DH) closed-loop control, 2) insulin-only single-hormone (SH) closed-loop control, and 3) PLGS system. The primary end point was percentage time in hypoglycemia ( RESULTS DH reduced hypoglycemia compared with SH during and after exercise (DH 0.0% [interquartile range 0.0–4.2], SH 8.3% [0.0–12.5], P = 0.025). There was an increased time in hyperglycemia (>180 mg/dL) during and after exercise for DH versus SH (20.8% DH vs. 6.3% SH, P = 0.038). Mean glucose during the entire study duration was DH, 159.2; SH, 151.6; and PLGS, 163.6 mg/dL. Across the entire study duration, DH resulted in 7.5% more time in target range (70–180 mg/dL) compared with the PLGS system (71.0% vs. 63.4%, P = 0.044). For the entire study duration, DH had 28.2% time in hyperglycemia vs. 25.1% for SH (P = 0.044) and 34.7% for PLGS (P = 0.140). Four participants experienced nausea related to glucagon, leading three to withdraw from the study. CONCLUSIONS The glucagon formulation demonstrated feasibility in a closed-loop system. The DH system reduced hypoglycemia during and after exercise, with some increase in hyperglycemia.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::239d793cfe1b212548d7861dba424a0dTest
https://doi.org/10.2337/dc19-2267Test

المؤلفون: Antonietta Canna, Pavel Filip, Elizabeth R. Seaquist, Amir Moheet, Petr Bednarik, Xiufeng Li, Anjali Kumar, Evan Olawsky, Lynn E. Eberly, Heidi Gröhn, Silvia Mangia

المصدر: Diabetes

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cerebellum, Pathology, medicine.medical_specialty, Complications, Adolescent, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Inflammation, Type 2 diabetes, Young Adult, 03 medical and health sciences, Myelin, 0302 clinical medicine, Internal Medicine, medicine, Humans, Retrospective Studies, Type 1 diabetes, medicine.diagnostic_test, business.industry, Brain, Magnetic resonance imaging, Blood flow, Middle Aged, medicine.disease, Diabetes Mellitus, Type 1, 030104 developmental biology, medicine.anatomical_structure, Cerebral blood flow, Case-Control Studies, Female, medicine.symptom, business

الوصف: Even though well known in type 2 diabetes, the existence of brain changes in type 1 diabetes (T1D) and both their neuroanatomical and clinical features are less well characterized. To fill the void in the current understanding of this disease, we sought to determine the possible neural correlate in long-duration T1D at several levels, including macrostructural, microstructural cerebral damage, and blood flow alterations. In this cross-sectional study, we compared a cohort of 61 patients with T1D with an average disease duration of 21 years with 54 well-matched control subjects without diabetes in a multimodal MRI protocol providing macrostructural metrics (cortical thickness and structural volumes), microstructural measures (T1-weighted/T2-weighted [T1w/T2w] ratio as a marker of myelin content, inflammation, and edema), and cerebral blood flow. Patients with T1D had higher T1w/T2w ratios in the right parahippocampal gyrus, the executive part of both putamina, both thalami, and the cerebellum. These alterations were reflected in lower putaminal and thalamic volume bilaterally. No cerebral blood flow differences between groups were found in any of these structures, suggesting nonvascular etiologies of these changes. Our findings implicate a marked nonvascular disruption in T1D of several essential neural nodes engaged in both cognitive and motor processing.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c1ae40dea36315feffa31a00a6b7b5fTest
https://doi.org/10.2337/db19-1100Test

المؤلفون: Deirdre K. Luttrell, Miran A. Jaffa, Maria F. Lopes-Virella, Ionut Bebu, Timothy J. Lyons, Dcct, Kelly J. Hunt, Ayad A. Jaffa, John M. Lachin, Barbara H. Braffett, Louis M. Luttrell

المصدر: Diabetes

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, medicine.medical_specialty, Complications, endocrine system diseases, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Cohort Studies, Young Adult, 03 medical and health sciences, 0302 clinical medicine, immune system diseases, Risk Factors, Internal medicine, Diabetes mellitus, Epidemiology, Internal Medicine, medicine, Humans, Longitudinal Studies, cardiovascular diseases, Type 1 diabetes, business.industry, Hazard ratio, Kallikrein, medicine.disease, Diabetes Mellitus, Type 1, 030104 developmental biology, Cardiovascular Diseases, Cohort, Cardiology, Female, Kallikreins, business, Mace, Cohort study

الوصف: We determined the relationship between plasma kallikrein and cardiovascular disease (CVD) outcomes as well as major adverse cardiovascular events (MACE) in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) cohort of type 1 diabetes (T1D). Plasma kallikrein levels were measured longitudinally in 693 subjects at DCCT baseline (1983–1989), midpoint (1988–1991), and end (1993) and at EDIC years 4–6 (1997–1999), 8–10 (2001–2003), and 11–13 (2004–2006). Cox proportional hazards regression models assessed the association between plasma kallikrein levels and the risk of CVD. In unadjusted models, higher plasma kallikrein levels were associated with higher risk of any CVD during DCCT/EDIC (hazard ratio [HR] = 1.16 per 20 nmol/L higher levels of plasma kallikrein; P = 0.0177) as well as over the EDIC-only period (HR = 1.22; P = 0.0024). The association between plasma kallikrein levels and the risk of any CVD remained significant during the EDIC follow-up after adjustment for age and mean HbA1c (HR = 1.20; P = 0.0082) and in the fully adjusted model for other CVD risk factors (HR = 1.17; P = 0.0330). For MACE, higher plasma kallikrein levels were associated with higher risk in the unadjusted (HR = 1.25; P = 0.0145), minimally adjusted (HR = 1.23; P = 0.0417, and fully adjusted (HR = 1.27; P = 0.0328) models for EDIC only. These novel findings indicate that plasma kallikrein level associates with the risk of any CVD and MACE in T1D individuals.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df276f24fc556298f2ae5b80a03c5b0fTest
https://doi.org/10.2337/db20-0427Test